James R O'Dell1,2, Mary T Brophy3,4, Michael H Pillinger5,6, Tuhina Neogi7, Paul M Palevsky8,9, Hongsheng Wu3,10, Anne Davis-Karim11, Jeff A Newcomb1,2, Ryan Ferguson3, David Pittman11, Grant W Cannon12, Thomas Taylor13,14, Robert Terkeltaub15, Amy C Cannella1,2, Bryant R England1,2, Lindsay N Helget1,2, Ted R Mikuls1,2. 1. Veterans Affairs (VA) Nebraska-Western Iowa Health Care System, Omaha, Nebraska. 2. Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska. 3. VA Boston Cooperative Studies Program Coordinating Center, Boston. 4. School of Medicine, VA Boston Health Care System, Boston University, Boston. 5. VA New York Harbor Health Care System, New York. 6. NYU Grossman School of Medicine, New York. 7. Boston University School of Medicine, Boston. 8. VA Pittsburgh Health Care System, Pittsburgh. 9. University of Pittsburgh School of Medicine, Pittsburgh. 10. Wentworth Institute of Technology, Boston. 11. VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, NM. 12. VA Salt Lake City Health Care System, University of Utah, Salt Lake City. 13. White River Junction VA Medical Center, White River Junction, VT. 14. Dartmouth Geisel School of Medicine, Hanover, NH. 15. VA San Diego Health Care System, San Diego, CA.
Abstract
BACKGROUND: The relative efficacy and safety of allopurinol and febuxostat when used according to current guidelines for the treatment of hyperuricemia are unknown. This double-blind noninferiority trial examined these issues. METHODS: Participants with gout and hyperuricemia (with at least 33% having stage 3 chronic kidney disease) were randomly assigned to allopurinol or febuxostat in this 72-week trial, with doses titrated to target serum urate. The trial had three phases: titration (weeks 0 to 24), maintenance (weeks 25 to 48), and observation (weeks 49 to 72). Allopurinol and febuxostat were initiated at daily doses of 100 and 40 mg, with maximum titration to 800 and 120 mg, respectively. Antiinflammatory prophylaxis was given during phases 1 and 2. The primary end point was the proportion of patients experiencing one or more flares during phase 3, with a prespecified noninferiority margin of less than 8 percentage points between allopurinol and febuxostat. Secondary end points included efficacy in patients with chronic kidney disease, proportion achieving target serum urate levels, and serious adverse events. RESULTS: This study included 940 participants; 20.1% withdrew, with similar proportions in treatment arms. During phase 3, 36.5% of allopurinol-treated participants had one flare or more compared with 43.5% of febuxostat-treated participants (P<0.001 for noninferiority). Overall, 80% of participants achieved mean target urates during phase 2 with no differences by treatment. There were no treatment differences (including cardiovascular events) in serious adverse events. CONCLUSIONS: Allopurinol and febuxostat achieved serum urate goals in patients with gout; allopurinol was noninferior to febuxostat in controlling flares. Similar outcomes were noted in participants with stage 3 chronic kidney disease. (Funded by the Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development; ClinicalTrials.gov identifier, NCT02579096.).
BACKGROUND: The relative efficacy and safety of allopurinol and febuxostat when used according to current guidelines for the treatment of hyperuricemia are unknown. This double-blind noninferiority trial examined these issues. METHODS: Participants with gout and hyperuricemia (with at least 33% having stage 3 chronic kidney disease) were randomly assigned to allopurinol or febuxostat in this 72-week trial, with doses titrated to target serum urate. The trial had three phases: titration (weeks 0 to 24), maintenance (weeks 25 to 48), and observation (weeks 49 to 72). Allopurinol and febuxostat were initiated at daily doses of 100 and 40 mg, with maximum titration to 800 and 120 mg, respectively. Antiinflammatory prophylaxis was given during phases 1 and 2. The primary end point was the proportion of patients experiencing one or more flares during phase 3, with a prespecified noninferiority margin of less than 8 percentage points between allopurinol and febuxostat. Secondary end points included efficacy in patients with chronic kidney disease, proportion achieving target serum urate levels, and serious adverse events. RESULTS: This study included 940 participants; 20.1% withdrew, with similar proportions in treatment arms. During phase 3, 36.5% of allopurinol-treated participants had one flare or more compared with 43.5% of febuxostat-treated participants (P<0.001 for noninferiority). Overall, 80% of participants achieved mean target urates during phase 2 with no differences by treatment. There were no treatment differences (including cardiovascular events) in serious adverse events. CONCLUSIONS: Allopurinol and febuxostat achieved serum urate goals in patients with gout; allopurinol was noninferior to febuxostat in controlling flares. Similar outcomes were noted in participants with stage 3 chronic kidney disease. (Funded by the Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development; ClinicalTrials.gov identifier, NCT02579096.).
Authors: Jiaojiao Jing; Jan T Kielstein; Ulla T Schultheiss; Thomas Sitter; Stephanie I Titze; Elke S Schaeffner; Mara McAdams-DeMarco; Florian Kronenberg; Kai-Uwe Eckardt; Anna Köttgen Journal: Nephrol Dial Transplant Date: 2014-11-13 Impact factor: 5.992
Authors: Ted R Mikuls; T Craig Cheetham; Gerald D Levy; Nazia Rashid; Artak Kerimian; Kimberly J Low; Brian W Coburn; David T Redden; Kenneth G Saag; P Jeffrey Foster; Lang Chen; Jeffrey R Curtis Journal: Am J Med Date: 2018-11-29 Impact factor: 4.965
Authors: Angelo L Gaffo; Nicola Dalbeth; Kenneth G Saag; Jasvinder A Singh; Elizabeth J Rahn; Amy S Mudano; Yi-Hsing Chen; Ching-Tsai Lin; Sandra Bourke; Worawit Louthrenoo; Janitzia Vazquez-Mellado; Hansel Hernández-Llinas; Tuhina Neogi; Ana Beatriz Vargas-Santos; Geraldo da Rocha Castelar-Pinheiro; Rodrigo B C Amorim; Till Uhlig; Hilde B Hammer; Maxim Eliseev; Fernando Perez-Ruiz; Lorenzo Cavagna; Geraldine M McCarthy; Lisa K Stamp; Martijn Gerritsen; Viktoria Fana; Francisca Sivera; William Taylor Journal: Arthritis Rheumatol Date: 2018-02-06 Impact factor: 10.995
Authors: Michael Chen-Xu; Chio Yokose; Sharan K Rai; Michael H Pillinger; Hyon K Choi Journal: Arthritis Rheumatol Date: 2019-04-15 Impact factor: 10.995
Authors: Michael M Givertz; Kevin J Anstrom; Margaret M Redfield; Anita Deswal; Haissam Haddad; Javed Butler; W H Wilson Tang; Mark E Dunlap; Martin M LeWinter; Douglas L Mann; G Michael Felker; Christopher M O'Connor; Steven R Goldsmith; Elizabeth O Ofili; Mitchell T Saltzberg; Kenneth B Margulies; Thomas P Cappola; Marvin A Konstam; Marc J Semigran; Steven E McNulty; Kerry L Lee; Monica R Shah; Adrian F Hernandez Journal: Circulation Date: 2015-04-14 Impact factor: 29.690
Authors: Stefan M Nidorf; Aernoud T L Fiolet; Arend Mosterd; John W Eikelboom; Astrid Schut; Tjerk S J Opstal; Salem H K The; Xiao-Fang Xu; Mark A Ireland; Timo Lenderink; Donald Latchem; Pieter Hoogslag; Anastazia Jerzewski; Peter Nierop; Alan Whelan; Randall Hendriks; Henk Swart; Jeroen Schaap; Aaf F M Kuijper; Maarten W J van Hessen; Pradyot Saklani; Isabel Tan; Angus G Thompson; Allison Morton; Chris Judkins; Willem A Bax; Maurits Dirksen; Marco Alings; Graeme J Hankey; Charley A Budgeon; Jan G P Tijssen; Jan H Cornel; Peter L Thompson Journal: N Engl J Med Date: 2020-08-31 Impact factor: 91.245